Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib-R-CHOP in DLBCL
NCT04604067Phase 2Active, not recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2021
- Primary completion
- Jan 2029
- Countries
- 2
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in diffuse large B-cell lymphoma (DLBCL), sponsored by Swiss Group for Clinical Cancer Research. Started Jun 2021; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04604067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604067.